New CBD Data and Data Collection Methods Are Needed

Relative to the FDA posts about studying CBD further, another important factor are the rates of CBD use. The rates of use of CBD, and also for the use of specific CBD containing products, are not clearly understood. A question arises as to what the risks and commonality associated with adverse effects in those who take CBD are. What specific people have the greatest exposure to CBD, and what products in particular are they taking? Another question is whether or not they are also taking other over the counter products, as well as prescription drugs, concomitantly with CBD. This further introduces the situation as to what interactions could occur between CBD products and other products, beyond what the FDA has found and reported currently.

So far, data collection does not yet have codes specific to identifying CBD products in a precise manner. The type of studies which are needed for further CBD study are longitudinal ones. These studies provide data about the subject\’s health over a long or extended period of time. They are necessary to better understand the long term effects on health from CBD use over time.

Over the upcoming months, the FDA plans to develop and streamline research projects which will utilize certain methods that address the lack of current CBD research data capacity.